Funding
Series B · Biotech

BreezeBio raises $60M Series B

BreezeBio raised $60 million in Series B financing announced in February.

Updated Oct 16, 2026By RoundOS Funding desk

Backers include Yuanta Investment, DSC Investment, SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, DAYLI Partners, Pathway Investment, LoftyRock Investment, Korea Investment Partners, Woori Venture Partners, KDB Silicon Valley and ACVC Partners.

The company develops genetic medicines using non-viral nanoparticle delivery across tissues.

Funding history

Series B · This round$60M

Sources

  1. BreezeBioprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related